Our member, Idevax, a pioneering company specializing in innovative skin drug delivery technology, announced the successful closing of a €3 million Series A funding round. The investment was led by Myosotis Investments, with participation from existing shareholders and the management.
The fresh capital will fuel Idevax’s mission to become a global leader in skin drug delivery solutions. The funds will be used to accelerate the development and commercialization of the company’s proprietary technology for therapeutic and prophylactic vaccination. Additionally, the investment will support the generation of further clinical evidence to solidify Idevax’s position in the market. Idevax’s flagship product line, VAX-ID, is a cutting-edge platform designed for accurate and reliable vaccination and drug delivery through the skin. VAX-ID offers a high level of ease of use and is currently being utilized in (pre)clinical studies in Europe and the United States under Research Use/ Investigational Use Only (RUO/IUO) labeling.
With the infusion of new capital, Idevax will accelerate its efforts to achieve full commercialization of VAX-ID in both Europe and the United States. This will involve obtaining the necessary certifications, including CE marking as Class IIa in Europe and FDA approval as a Class II medical device in the United States.
To support its ambitious growth plans, Idevax is expanding its team. Key hires will include experts in Clinical Affairs, Product Design, Business Development, and Manufacturing. These additions will strengthen Idevax’s capabilities and position the company for continued success. “We are thrilled to have secured this significant investment from Myosotis Investments and our existing shareholders,” said Vanessa Vankerckhoven, co-founder and CEO of Idevax. “This funding will enable us to accelerate our development efforts and bring our groundbreaking technology to market, ultimately improving patient outcomes and revolutionizing the way therapeutics and vaccines are delivered.”
Co-founder and CTO Koen Beyers: “A key milestone in the company’s growth is the planned upscaling of its manufacturing operations in Belgium early in 2025. This expansion will enable Idevax to meet the increasing demand for its innovative products and strengthen its supply chain capabilities.”
“I am excited to help to strengthening the position of IDEVAX, enabling them to deliver an innovative medical device that facilitates accurate delivery of vaccines. I am looking forward to collaborating with the management and the team on their entrepreneurial journey.” Wietse Mulder PhD, managing partner of Myosotis Investments B.V.
About Idevax
Idevax is an ISO13485 certified medical device company based in Antwerp, Belgium, founded in December 2020. Idevax is dedicated to developing innovative skin drug delivery solutions. The company’s proprietary technology offers a safe, effective, and convenient alternative to traditional drug delivery methods. Idevax is committed to improving patient comfort by providing cutting-edge solutions for a variety of therapeutic and prophylactic applications.
About Myosotis Investments
Myosotis Investments is a venture capital firm focused on investing in innovative companies with high-growth potential. The firm supports entrepreneurs in building successful mission driven businesses by providing capital, strategic guidance, and industry expertise.
https://www.linkedin.com/company/myosotisinvestments/
For more information, contact:
Vanessa Vankerckhoven
CEO & Founder
Vanessa.vankerckhoven@idevax.com